The state of Texas currently has 887 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including Houston, Dallas, San Antonio and Austin.
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
Recruiting
This study will include patients with invasive cervical cancer that wish to keep their fertility as much as possible in the future after treatment. Patients who receive surgery alone may experience long-term side effects including infertility. The purpose of this research study is to determine whether giving neo-adjuvant chemotherapy prior to surgery can maintain fertility in patients with invasive cervical cancer. The neo-adjuvant chemotherapy will consist of a platinum-based chemotherapy dru... Read More
Gender:
Female
Ages:
Between 18 years and 40 years
Trial Updated:
11/03/2023
Locations: MD Anderson Cancer Centre, Houston, Texas
Conditions: Cervical Cancer
Lenvatinib in Locally Advanced Invasive Thyroid Cancer
Recruiting
This research is being done to evaluate the safety and efficacy of neoadjuvant lenvatinib on surgical outcomes of patients with invasive extrathyroidal differentiated thyroid cancer (DTC). This research study involves a study drug called lenvatinib
Gender:
All
Ages:
18 years and above
Trial Updated:
11/01/2023
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Differentiated Thyroid Cancer, Advanced Cancer
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
Recruiting
This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR502 administered as a monotherapy and in combination with cemiplimab in subjects with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/31/2023
Locations: NEXT Austin, Austin, Texas +2 locations
Conditions: Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Platinum-resistant Ovarian Cancer, Cutaneous Squamous Cell Carcinoma
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
Recruiting
This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR2805 administered as a monotherapy and in combination with anti-cancer agents in subjects with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/31/2023
Locations: NEXT Austin, Austin, Texas +1 locations
Conditions: Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Leiomyosarcoma, Liposarcoma
Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer
Recruiting
This is a multi-centre, Phase 1/2, open-label clinical trial of the VTP-850 prime-boost immunotherapeutic in men with biochemical recurrence after definitive local therapy for prostate cancer.
Gender:
Male
Ages:
18 years and above
Trial Updated:
10/24/2023
Locations: Houston Methodist Urology Associates, Texas Medical Center, Houston, Texas
Conditions: Prostate Cancer
Strategic Targeting for Optimal Prevention of Cancer
Recruiting
The primary goal of the study is to record data over the observation period to evaluate the clinical benefit of using hereditary cancer genomic diagnostics to assess overall hereditary genetic cancer risk profile and to help guide physicians to pursue preventative measures, which may lead to early detection and treatment of the condition.
Gender:
All
Ages:
65 years and above
Trial Updated:
10/19/2023
Locations: Sunbeam Clinical, Prosper, Texas
Conditions: Early Detection of Cancer
EO4010 in Previously Treated Metastatic Colorectal Carcinoma
Recruiting
Open-label multicenter study
Gender:
All
Ages:
18 years and above
Trial Updated:
10/19/2023
Locations: MD Anderson, Houston, Texas
Conditions: Colorectal Cancer Metastatic
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Recruiting
A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.
Gender:
All
Ages:
12 years and above
Trial Updated:
10/18/2023
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer, DIPG Brain Tumor, Ovary Cancer, Breast Cancer, Papillary Thyroid Cancer, Head and Neck Cancer, Gastric Cancer, Nsclc, Mesotheliomas Pleural, Mesothelioma Peritoneum, Esophageal Cancer, Diffuse Midline Glioma, H3 K27M-Mutant, Endometrial Cancer, Cervical Cancer, Melanoma, Colorectal Cancer, Glioma, Malignant
Prostate-Specific Membrane Antigen (PSMA) Radionuclide Therapy
Recruiting
This study is a single-center registry study collecting clinical data regarding the treatment of PSMA-positive metastatic castration-resistant prostate cancer treated with PSMA radionuclide therapy per the treating physician's discretion. Clinical data from candidates for or who undergo the PSMA procedure at Methodist Dallas Medical Center from August 2022 to August 2027 will be collected after discharge and patients will undergo clinical follow-up per the treating physician's discretion.
Gender:
Male
Ages:
18 years and above
Trial Updated:
10/18/2023
Locations: Methodist Dallas Medical Center, Dallas, Texas
Conditions: Prostate Cancer
Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC
Recruiting
To determine the efficacy of combined afatinib and prednisone in previously treated advanced squamous NSCLC
Gender:
All
Ages:
18 years and above
Trial Updated:
10/17/2023
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Advanced Squamous Non Small Cell Lung Cancer
Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers
Recruiting
To compare the symptoms of patients who have a MIPG to the symptoms of patients who have a MITG.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/11/2023
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Gastrostomy, Gastric, GastroEsophageal Cancer
Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer
Recruiting
The investigators are conducting this study with men that have prostate cancer and are getting standard of care treatment with the drugs abiraterone acetate and prednisone. The study will follow men with prostate cancer from initiation of participation in the study and for up to 10 years. The reason for the study is that researchers think that there may be a connection between the race and ethnicity of men with prostate cancer and how well the standard treatments work for the participants.
Gender:
Male
Ages:
18 years and above
Trial Updated:
10/10/2023
Locations: Ben Taub General Hospital, Houston, Texas +2 locations
Conditions: Prostate Cancer Metastatic, Prostate Cancer